EconPapers    
Economics at your fingertips  
 

Details about Mary K. Olson

Homepage:http://murphy.tulane.edu/people/mary-k-olson/
Workplace:Department of Economics, Tulane University, (more information at EDIRC)

Access statistics for papers by Mary K. Olson.

Last updated 2021-01-07. Update your information in the RePEc Author Service.

Short-id: pol152


Jump to Journal Articles

Working Papers

1992

  1. Pharmaceutical Expenditure and Regulatory Policy in the NHS
    Working Papers, Washington St. Louis - School of Business and Political Economy

Journal Articles

2021

  1. New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children?
    Health Economics, 2021, 30, (1), 144-164 Downloads

2018

  1. Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity
    American Journal of Health Economics, 2018, 4, (3), 321-357 Downloads
    Also in American Journal of Health Economics, 2018, 4, (3), 321-357 (2018) Downloads View citations (1)

2013

  1. Eliminating the U.S. drug lag: Implications for drug safety
    Journal of Risk and Uncertainty, 2013, 47, (1), 1-30 Downloads View citations (2)

2008

  1. The risk we bear: The effects of review speed and industry user fees on new drug safety
    Journal of Health Economics, 2008, 27, (2), 175-200 Downloads View citations (10)

2004

  1. Are novel drugs more risky for patients than less novel drugs?
    Journal of Health Economics, 2004, 23, (6), 1135-1158 Downloads View citations (14)

2002

  1. Pharmaceutical Policy Change and the Safety of New Drugs
    Journal of Law and Economics, 2002, 45, (S2), 615-642 Downloads View citations (11)

2000

  1. Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA
    Journal of Economics & Management Strategy, 2000, 9, (3), 363-395 Downloads View citations (2)

1999

  1. Agency Rulemaking, Political Influences, Regulation, and Industry Compliance
    Journal of Law, Economics, and Organization, 1999, 15, (3), 573-601 View citations (7)

1997

  1. Firm Characteristics and the Speed of FDA Approval
    Journal of Economics & Management Strategy, 1997, 6, (1), 377-401 Downloads View citations (15)

1996

  1. Substitution in Regulatory Agencies: FDA Enforcement Alternatives
    Journal of Law, Economics, and Organization, 1996, 12, (2), 376-407 View citations (11)

1995

  1. Regulatory Agency Discretion among Competing Industries: Inside the FDA
    Journal of Law, Economics, and Organization, 1995, 11, (2), 379-405 View citations (14)
  2. The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D
    International Journal of the Economics of Business, 1995, 2, (1), 51-64 Downloads View citations (1)

1994

  1. Political Influence and Regulatory Policy: The 1984 Drug Legislation
    Economic Inquiry, 1994, 32, (3), 363-82 View citations (1)
 
Page updated 2021-01-08